Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • 12 hours ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference: Exelixis is scheduled to present at 1:10 p.m. ET / 10:10 a.m. PT on Tuesday, March 3 in Boston. Leerink Partners 2026 Global Healthcare Conference: Exelixis is scheduled to present at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, March 10 in Miami. 2026 Citizens Life Scie.

Business Wire • 7 hours ago

Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026

Exelixis' main franchise has helped it perform well in recent years. The biotech company is developing new, promising cancer drugs.

The Motley Fool • Feb 20, 2026

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Feb 20, 2026

A Dive into Exelixis (EXEL) International Revenue Trends and Forecasts

Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks Investment Research • Feb 16, 2026

Here's Why Exelixis (EXEL) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Feb 13, 2026

Exelixis Reports Solid Earnings—Are New Highs Back on the Table?

Exelixis Inc. NASDAQ: EXEL stock is down about 2% in early trading the day after the company delivered a solid, but mixed earnings report. The company reported earnings per share (EPS) of 94 cents, which was 27% above the consensus estimate and 95% higher on a year-over-year (YoY) basis.

MarketBeat • Feb 12, 2026

EXEL or LQDA: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Liquidia Corporation (LQDA). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Feb 12, 2026

EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus

Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.

Zacks Investment Research • Feb 11, 2026

Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript

Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 11, 2026